Literature DB >> 9265724

Engineering antibodies for imaging and therapy.

P Carter1, A M Merchant.   

Abstract

Several advances made during the past year will probably facilitate the development of therapeutic antibodies. Most notably, significant progress has been made in the rapid isolation of high affinity human antibodies from phage display libraries and by immunization of transgenic mice. The therapeutic potential of bispecific antibody fragments and Fc-containing proteins has been greatly enhanced by improved production methods. The utility of radiolabeled antibody fragments has been improved by the development of site-specific labeling methods and by the advent of the 'minibody', an engineered fragment that has proved to be highly successful for tumor imaging in mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9265724     DOI: 10.1016/s0958-1669(97)80067-5

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  9 in total

1.  Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein.

Authors:  Ekaterina O Serebrovskaya; Eveline F Edelweiss; Oleg A Stremovskiy; Konstantin A Lukyanov; Dmitry M Chudakov; Sergey M Deyev
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-20       Impact factor: 11.205

Review 2.  Glioblastoma cancer stem cells: Biomarker and therapeutic advances.

Authors:  Kelli B Pointer; Paul A Clark; Michael Zorniak; Bahauddeen M Alrfaei; John S Kuo
Journal:  Neurochem Int       Date:  2014-03-19       Impact factor: 3.921

3.  Generation of native bovine mAbs by phage display.

Authors:  P M O'Brien; R Aitken; B W O'Neil; M S Campo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 4.  Techniques for molecular imaging probe design.

Authors:  Fred Reynolds; Kimberly A Kelly
Journal:  Mol Imaging       Date:  2011-12       Impact factor: 4.488

5.  A general approach to antibody thermostabilization.

Authors:  Audrey D McConnell; Xue Zhang; John L Macomber; Betty Chau; Joseph C Sheffer; Sorena Rahmanian; Eric Hare; Vladimir Spasojevic; Robert A Horlick; David J King; Peter M Bowers
Journal:  MAbs       Date:  2014       Impact factor: 5.857

6.  The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotype.

Authors:  P B Furtado; J E McElveen; L Gough; K L Armour; M R Clark; H F Sewell; F Shakib
Journal:  Mol Pathol       Date:  2002-10

Review 7.  Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology.

Authors:  Hisataka Kobayashi; Peter L Choyke; Mikako Ogawa
Journal:  Curr Opin Chem Biol       Date:  2016-06-06       Impact factor: 8.822

Review 8.  Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.

Authors:  Frank R Brennan; Leigh Shaw; Mark G Wing; Christine Robinson
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.860

9.  Killing cancer cells by targeted drug-carrying phage nanomedicines.

Authors:  Hagit Bar; Iftach Yacoby; Itai Benhar
Journal:  BMC Biotechnol       Date:  2008-04-03       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.